Newsfeeds - Spark Newswire

1 minute read

Xeris Pharmaceuticals Q1 EPS $(0.25), Inline, Sales $21.90M Miss $23.59M Estimate

Today, 7:00 PM

Xeris Pharmaceuticals (NASDAQ:XERS) reported quarterly losses of $(0.25) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.30) per share from the same period last

XERS

12 minute read

Earnings Scheduled For May 11, 2022

By Benzinga Insights

Today, 7:00 PM

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

ACOR

1 minute read

Mizuho Maintains Buy on Xeris Biopharma Holdings, Lowers Price Target to $6

By Benzinga Newsdesk

Today, 7:00 PM

Mizuho analyst Vamil Divan maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and lowers the price target from $8 to $6.

XERS

1 minute read

SVB Leerink Maintains Outperform on Xeris Biopharma Holdings, Lowers Price Target to $6

By Benzinga Newsdesk

Today, 7:00 PM

SVB Leerink analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and lowers the price target from $8 to $6.

XERS

1 minute read

18 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 7:00 PM

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

ARDS

1 minute read

Xeris Biopharma Eyes High End Of FY21 Sales Outlook

By Vandana Singh

Today, 7:00 PM

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has

XERS

1 minute read

PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev

By Hal Lindon

Today, 7:00 PM

PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).

XERS

3 minute read

40 Biggest Movers From Friday

By Lisa Levin

Today, 7:00 PM

Gainers

AGE

3 minute read

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

By Shanthi Rexaline

Today, 7:00 PM

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.

ALNY

2 minute read

Mid-Afternoon Market Update: Dow Rises 50 Points; Nutriband Shares Spike Higher

By Lisa Levin

Today, 7:00 PM

Toward the end of trading Friday, the Dow traded up 0.14% to 36,449.17 while the NASDAQ fell 0.20% to 15,710.56. The S&P also rose, gaining 0.08% to 4,782.32.

ESBA